Showing 1136 results
-
Press release /Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data…
-
Press release /51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
-
Press release /Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
-
Press release /Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Press release /First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…
-
Press release /LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
-
Press release /Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-…
-
Story /By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs
-
Story /Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.
-
Story /Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.